Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study

Author:

Levy R A1,Vilela V S,Cataldo M J2,Ramos R C3,Duarte J LMB4,Tura B R5,Albuquerque E MN2,Jesús N R6

Affiliation:

1. Department of Rheumatology, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil; Hospital Universitário Pedro Ernesto, UERJ, Discipline of Rheumatology, Blvd 28 de Setembro 77/333, Vila Isabel 20550-013, Rio de Janeiro, RJ, Brazil

2. Department of Rheumatology, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

3. Department of Ophthalmology, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

4. Department of Pediatrics, Faculdade de Ciêdicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

5. Department of Medical Informatics, Faculdade de Ciências Méncias, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

6. Department of Obstetrics, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

Abstract

We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety. Twenty consecutive pregnant patients with similar characteristics were enrolled. The HCQ group included eight patients with systemic lupus erythematosus (SLE) and two with discoid lupus erythematosus (DLE). The placebo (PL) group included nine patients with SLE and one with DLE. The HCQ group had no flare-ups. SLEPDAI scores were similar at study entry, and at conclusion the placebo group had significantly higher scores. One patient had improvement of skin lesions and another of arthritis, allowing a decrease of prednisone dose. There were no retinal effects. Three patients in the PL group flared up, two with skin rashes, one also with arthritis and uveitis, and one (previously in remission on HCQ) with hemolytic anemia, polyserositis and anti-dsDNA antibody. Toxemia was diagnosed in only three patients in the PL group (one fetal death). Comparing prednisone dosage change, we noted a decrease in the HCQ and an increase in the PL group. Delivery age and Apgar scores were higher in the HCQ group. Neonatal examination did not reveal congenital abnormalities, nor did a neuroophthalmological and auditory evaluation at 1.5–3 y of age. In spite of the small number of patients studied, we noted beneficial effects of HCQ during lupus pregnancy, as measured by SLEPDAI and decrease in prednisone dose with no detriment to patients' health.

Publisher

SAGE Publications

Subject

Rheumatology

Cited by 333 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Antimalarial medications;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Neonatal lupus;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Issues with pregnancy in systemic lupus;Joint Bone Spine;2024-12

4. Risk of flare in patients with SLE in remission after hydroxychloroquine or chloroquine withdrawal;Joint Bone Spine;2024-12

5. Clinical recommendations on diagnostics and treatment of lupus nephritis (draft project);Nephrology and Dialysis;2024-08-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3